A compound that extends lifespan in a tiny nematode worm slows bone loss in aging mice. That surprising result comes from a longitudinal and functional study of 700 aging mice at the Buck Institute, a project that provides a treasure trove of data for researchers aiming to develop therapeutics to slow aging and age-related diseases.
The study is currently online in the Journal of Bone and Mineral Research Plus.
The project, which involved five Buck labs and took several years to complete, involved serially profiling the individual mice as they aged while testing several therapeutics that extended lifespan in simple model organisms or reduced neurological disease in mice.
Researchers established rates of change for clinically significant parameters in untreated mice including kyphosis, blood glucose, body composition, activity, metabolic measures and detailed parameters of skeletal aging in bone. The study involved collecting and analyzing terabytes of data over several years.
This is a unique resource that comes from a study of multiple phenotypes of aging that had never been looked at before. Our hope is that our data will enable those working on pre-clinical studies to essentially model experiments virtually, in order to provide a starting point for testing other interventions in mice."
Simon Melov, PhD, Study Senior Author and Professor, Buck Institute for Research on Aging
Benzoxazole, the compound that slowed bone aging by up to 31% over the course of a year's treatment in the mice, was first identified as one of five compounds that extended nematode lifespan in the Lithgow lab in a study that appeared in Nature in 2011.
"If you have a therapeutic that extends lifespan in a simple animal that has no bone whatsoever, you certainly wouldn't predict that it would slow the rate of bone aging in a mammal," said Gordon Lithgow, PhD, Buck professor and Vice President. "It's obvious that aging-related pathways have been conserved during evolution. This new finding is a great example of the utility of screening compounds in simple animals as the starting point to look for unexpected and surprising benefits in mammals." In the Nature article, benzoxazole appeared to suppress age-related protein aggregation. The mechanism of action in mouse bone is still under study, although researchers say the compound appears to slow the reabsorption of osteoclasts, bone cells that are active during growth and healing.
Melov says the findings in the large study are relevant to humans, especially in regards to pre-clinical phenotypes. "The metrics we used are all directly applicable to aging in humans. They literally have direct clinical correlates to the types of things you would measure in humans." For example, for the first time researchers witnessed spontaneous fractures in aging mouse femurs. Melov says they occurred in 2.5% of the mouse population, not dissimilar to the 1 -2.7% incidence of hip fractures in people over the age of 65. He also notes that they developed a new unbiased method for evaluating kyphosis, an age-related curvature of the spine, and may pave the way for testing new interventions.
"We think using this new database could save substantial resources for those wanting to do pre-clinical studies of interventions," said Melov. "If someone wants to test a compound against a particular aging phenotype this database could provide information about how many mice are needed for the experiments and how long it would likely take to see results."
Evans, D S., et al. (2021) Longitudinal Functional Study of Murine Aging: A Resource for Future Study Designs. Journal of Bone and Mineral Research Plus. doi.org/10.1002/jbm4.10466.